NewAmsterdam Pharma Co N.V. (NAMS) — key financial figures for fiscal year 2025 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2025)

$22.5M

Net Income/Loss (FY2025)

-$203.8M

Total Assets (FY2025)

$769.3M

Total Equity (FY2025)

$683.4M

Cash Flows from Operating Activities (FY2025)

-$147.8M

Source: NewAmsterdam Pharma Co N.V. 10-K filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.